Saralasin
As of the edition of 20 October 2026, Saralasin is a protein: marketed, first approved in 1982 (US); acts on AGTR1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Protein
- Brand name
- Sarenin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Procter And Gamble
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Saralasin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | P30556 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Procter And Gamble | Applicant |